Lupin receives USFDA approval for anti-diabetes drug: Report

17 Jul 2015 Evaluate

Pharma Major Lupin, has reportedly received an approval from the USFDA for PrandiMet (also known as Prandin) generic, which is used for treatment of type 2 diabetes. The product is expected to have sales of $200-$300 million in the US. Danish pharma company Novo Nordisk is the innovator of the drug that has been approved to lower blood glucose in adult patients.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.

Lupin Share Price

2132.00 10.35 (0.49%)
29-Jan-2026 14:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1593.75
Dr. Reddys Lab 1208.30
Cipla 1322.25
Zydus Lifesciences 889.75
Lupin 2132.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×